Jim Cramer
Eli Lilly’s big GLP-1 investment — plus, what we want from 4 portfolio stock earnings
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Friday’s key moments. 1. Wall Street was bouncing higher Friday after, as Jim Cramer put it, a “really bad day” in the prior session. Thursday’s late-day decline happened as bond yields rose on […]
Read More
The stock market gets nailed by the Fed, again. Plus, Starbucks’ quiet comeback
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. (We’re no longer recording the audio, so we can get this new written feature to members as quickly as possible.) Fed foils stocks : The market […]
Read More
We’re encouraged by an activist’s willingness to buy an Abbott rival, look past baby formula suits
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. (We’re no longer recording the audio, so we can get this new written feature to members as quickly as possible.) No big swings : The market […]
Read More
Eli Lilly stock hits new highs after a regulatory win in China. This is a big deal
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Tuesday’s key moments. The Nasdaq edged lower Tuesday, pulling back from record highs the session before. Jim Cramer described the market as overall “benign,” while the S & P 500 and Dow also […]
Read More
Danaher’s rally shows how sticking with a troubled stock of a good company can pay off
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. (We’re no longer recording the audio, so we can get this new written feature to members as quickly as possible.) Market talk : The S & […]
Read More
It’s no surprise to see Amazon shares lower after cloud CEO shakeup
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Tuesday’s key moments. U.S. stocks were little changed Tuesday as the market digested hotter-than-expected inflation data. April’s producer price index print came in above estimates , further complicating the timeline for Federal Reserve […]
Read More
Jim Cramer’s Friday ideas on 5 shares: Cloudflare, DraftKings, Expedia, Reserving and Hershey
Jim Cramer’s every day fast hearth looks at shares in the news exterior the CNBC Investing Club portfolio. Cloudflare : Shares of the content material shipping and delivery network were sinking 16% immediately after the midpoint of the company’s second-quarter revenue outlook arrived in brief of analyst estimates. “Persons sense they are losing share. I […]
Read More
Jim Cramer says GE Healthcare’s unwarranted post-earnings plunge is a buying opportunity
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. (We’re no longer recording the audio, so we can get this new written feature to members as quickly as possible.) April showers : The Dow Jones […]
Read More
Eli Lilly assures investors it can overcome the high-quality problem of too much demand
Eli Lilly ‘s raised guidance stole the show Tuesday, offsetting mixed first-quarter results and propelling shares higher by nearly 6%. The numbers leave little doubt that the long-term Eli Lilly success story remains intact, as demand for its new diabetes and obesity drugs, Mounjaro and Zepbound, outstrips supply. Revenue in the three months ended March […]
Read More
Promise of Eli Lilly’s weight-loss drug for sleep apnea adds another reason to own the stock
Eli Lilly ‘s weight-loss drug Zepbound showed promise as a treatment for sleep apnea — giving investors more confidence to keep owning the world’s most valuable health-care company even after it’s been crushing the S & P 500’s performance over the past three years. The study results released by Eli Lilly on Wednesday highlight the […]
Read More